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license (http://creativeimpairment (MCI) and Alzheimer’s disease (AD). Cumulative evidence suggests that apolipopro-
teins, complement system, and transthyretin are involved in AD pathogenesis by sequestration of am-
yloid b. However, there is no clinical study to assess the utility of “sequester proteins” in risk
assessment and/or diagnosis of MCI and AD.
Methods: Serum levels of sequester proteins and their clinical potential in cognitive decline assess-
ment were analyzed by longitudinal and cross-sectional studies using independent cohorts and were
confirmed by a prospective study.
Results: A combination of apolipoprotein A1, complement C3, and transthyretin achieved an area
under the curve of 0.89 (sensitivity 91% and specificity 80%) in MCI versus healthy controls and
also discriminated individuals with mild cognitive decline from healthy controls.
Discussion: A set of sequester proteins could be blood-based biomarkers for assessment of early
stages of cognitive decline.
 2015 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Alzheimer’s disease; Apolipoprotein; Biomarker; Complement system; Diagnostics; Mild cognitive impairment;Transthyretin1. Introduction
Biomarker discovery for neurologic disorders is chal-
lenging but rewarding because it facilitates early diagnosis,
monitors disease progression, and assesses response to med-
ical treatment. Currently, the number of people who have
been diagnosed with dementia worldwide is 35.6 million,
and it is predicted that this rate will increase to.100 milliontential conflicts of interest, K.U. serves as a board
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he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).people in 2050 [1]. In fact, 15% of individuals (4.86 million)
aged 65 years have been affected in Japan [2]. Diagnosis
and intervention at early stages of dementia may greatly
reduce the number of individuals suffering from this debili-
tating disease.
Alzheimer’s disease (AD) is the most common form of
dementia with .24 million people suffering from this
neurodegenerative disorder worldwide [3]. In the United
States, 5.2 million cases of AD were reported in 2014,
and this number is predicted to double by 2050 [4]. Mild
cognitive impairment (MCI) is a syndrome defined as
cognitive decline that is greater than expected for an indi-
vidual’s age and is regarded as a risk group for AD [5].
MCI is considered as a prestage of dementia, and without
clinical intervention, 40% of patients with MCI mayimer’s Association. This is an open access article under the CC BY-NC-ND
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the number of people with dementia, the development of
biomarkers for cognitive decline and intervention, which
may prevent the progression of MCI to dementia, is
urgently needed.
Histopathologically, AD is distinguished from other
neurologic diseases, including other types of dementia and
normal aging, by abundant deposits of fibrillar amyloid b
(b). Ab-derived diffusible ligands (ADDLs) cause abnormal
spine morphology and a significant decrease in spine density
[6]. ADDLs trigger synaptic dysfunction, which may lead to
memory loss in AD [7].
In healthy individuals, Ab may be removed by clearance
mechanisms such as phagocytosis by microglia.
Complement proteins sequestrate Ab via an innate immune
response in the brain [8]. Ab has been shown to act as a
proinflammatory agent causing the activation of the
complement system. C3, C4, and complement factor H
were seen to be present in Ab plaques in AD [9].
Overexpression of chemokines, such as macrophage
inflammatory protein 4 (MIP-4) [10], in microglia and
astrocytes has suggested the involvement of inflammation
in the brain. The presence of a2-macroglobulin is also a
genetic risk factor for AD, which may be involved in Ab
clearance [11].
Another group of sequester proteins, such as apolipo-
proteins (apolipoprotein E [apoE], apolipoprotein A1
[apoA1], and apolipoprotein J [apoJ]), bind to Ab to pre-
vent its aggregation and reduce its toxicity and are
involved in Ab clearance [12–14]. Transthyretin (TTR)
or pre-albumin has been found in cerebrospinal fluid
(CSF) as an Ab-binding protein and suppresses the
toxicity of oligomers [15,16].
Thus, these sequester proteins have neuroprotective func-
tions and may help delay the pathologic progression of AD
via Ab clearance. Considering the crucial role of these pro-
teins in disease pathogenesis, we hypothesized that
sequester proteins have a clinical potential for risk assess-
ment of cognitive impairment and for early diagnosis of
MCI and AD.
In this study, we analyzed peripheral biomarkers to
identify cognitive decline by focusing on proteins
involved in Ab sequestration and validated the clinical
utility of these proteins as biomarkers in identifying MCI
and AD by both longitudinal and cross-sectional cohort
studies.2. Methods
2.1. Participants and cohort size
In a longitudinal study, participants were recruited from
the “Tone Project” that was performed in Ibaraki, Japan
[17]. In the Tone cohort, 1270 available participants who
were 65 years and cognitively normal in 2001 were setas the baseline. Among them, 1024 participants were fol-
lowed up in 2005, and 584 participants were followed up
in 2008. Serum samples were collected in 2001, 2005, and
2008. Paired blood samples from the same participant in
2005 and 2008 were used in this study. Based on the diag-
nosis of participants followed up in 2012, we selected par-
ticipants with MCI due to AD from 2005 to 2008 and
excluded participants who progressed to other types of de-
mentia. After the selection of MCI/AD, we randomly
selected age-matched nondemented disease control
(NDC) subjects and adjusted its number with that of
MCI. We carefully chose samples in the NDC group in
2005 and 2008 from individuals who had also been diag-
nosed as NDC in 2001 and 2005, respectively. The serum
samples from participants were grouped as follows: group
1, NDC-NDC (n 5 20), comprised individuals who had re-
mained cognitively normal during the follow-up; group 2,
NDC-MCI (n 5 9), comprised participants who had pro-
gressed from normal to MCI; group 3, MCI-stable MCI
(sMCI)/AD (n 5 6), comprised participants who were
diagnosed with MCI in 2005 and MCI or AD in 2008.
See Supplementary Methods for details of the Tone
cohort.
In a cross-sectional study, patients were from the
Tsukuba University Hospital (Tsukuba, Japan) and were
set as the Tsukuba cohort. The sample size of the
Tsukuba cohort was 441 and included AD, MCI, other
types of dementia, and other psychiatric diseases; in
particular, we selected from participants with AD,
amnestic MCI (aMCI), and NDC. All cases that had the
mini-mental state examination (MMSE) score data were
included.
In a prospective study, a total of 258 participants from
Uji City, Kyoto, Japan, were enrolled to evaluate
biomarker suitability for the detection of cognitive
decline. APOE genotyping and MMSE were also
performed. Of the 258 participants, 64 were recruited
for further clinical diagnosis; among these, 23 had
MCI. To evaluate sequester proteins as biomarkers for
early stage cognitive impairment, we designated as
pre-MCI those participants with MMSE scores of 27–29.
In addition, regardless of the MMSE score, the
participants with decreased cerebral blood flow in the
parietal lobe, posterior cingulate gyrus, and precuneus
on single-photon emission computed tomography [18]
and/or those with atrophy of the hippocampus on
magnetic resonance imaging [19] were categorized as
pre-MCI.
In all cohort studies, participants with any psychiatric
illness according to the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition (DSM-IV)
criteria were excluded. Written informed consent was
obtained from all eligible participants. All protocols in
the present work were approved by the ethics committee
of each institute.
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The team reviewed the functional, medical, neurologic,
psychiatric, and neuropsychological data to reach a diag-
nostic consensus on dementia according to the DSM-IV
criteria.
Criteria for MCI were retrospectively applied among the
nondemented individuals after the conference. Consistent
with the standard criteria, for all subtypes of MCI
described in the following, the participants considered to
have MCI were required to have (1) objective impairment
in one cognitive domain based on the average of scores on
neuropsychological measures within that domain, and 1
standard deviation (SD) and 1.5 SD cutoffs derived from
normative corrections for age, years of education, and
sex; (2) essentially preserved activities of daily living; (3)
presence of memory complaints; and (4) no diagnosis of
dementia by group consensus.
First, for our subtype of aMCI single, memory impair-
ment was defined as a score ,1 or 1.5 SD below the
demographically corrected mean on the category-cued
recall test; performance on scores from all other cogni-
tive domains was required to fall within normal limits
(.1 or 1.5 SD below the demographically corrected
mean). Second, aMCI multiple was diagnosed in the pres-
ence of memory impairment in one or more cognitive do-
mains. Third, a diagnosis of nonamnestic MCI (naMCI)
single required cognitive impairment in a single non-
memory domain and normal performance scores in all
other cognitive domains. Finally, naMCI multiple was
diagnosed if impairment was seen in two of the four
non-memory domains and when the memory domain
score was within normal limits. Individuals without
dementia and MCI were defined as NDC. Diagnostic
criteria described previously were applied to all three
cohorts.
2.3. Serum sampling
Serum sample stored at 280C was transferred to the
laboratory for analysis, thawed on ice, and 40 mL of ali-
quots were generated. These aliquots were stored at
280C for immunoassay. Almost all the serum samples
were frozen and thawed two times, and some were frozen
and thawed three times. There were no significant changes
in protein levels for freeze-thaw cycles less than five (data
not shown).
2.4. Immunoassay
Serum levels of sequester proteins from all participants
were analyzed by a multi-immunoassay. Protein concen-
trations were determined using HNDG1-36K (comple-
ment C3 [C3], TTR, apoE, apoA1) and HNDG2-36K
kits (complement C4 [C4], MIP-4; EMD Millipore, Biller-
ica, MA, USA), following the manufacturers’ instructions.
The inactive form of C3 was proteolytically cleaved dur-ing activation, and the multiplex immunoassay specif-
ically detected an inactive form of C3 but not the
activated fragment.
2.5. Statistical analysis
A P value of .05 was considered significant. The
area under the curve (AUC) of the receiver operating
characteristic curve (ROC) was quantified by C-statistics.
The closest point to the upper left corner of the ROC
curve gave the optimum sensitivity and specificity values.
The least absolute shrinkage and selection operator
(LASSO) modeling using glmnet package (version 1.9-
5) for R (version 3.1.0) was used to evaluate the combi-
nation of multiple biomarkers. The softwares Origin
(version 7.5) (OriginLab Corp, Northampton, MA,
USA) and MedCalc (version 14.8.1) (MedCalc Software,
Mariakerke, Belgium) were used to perform statistical
analyses. See Supplementary Methods for details of
statistical analysis.3. Results
3.1. Longitudinal analysis of serum apoA1, apoE, C3, C4,
TTR, and MIP-4 levels in the Tone cohort
In 2005, 211 of 1024 participants who were followed up
were diagnosed with MCI. In 2008, among 584 participants
who were followed up, 92 additional participants were diag-
nosed withMCI. Therewere no significant distributional dif-
ferences for age, education, body mass index, and geriatric
depression scale [20] among the groups (Supplementary
Table 1). Both aMCI and naMCI were included.
As shown in the left panels of Fig. 1, longitudinal com-
parison of individuals in group 2 (NDC-MCI) who were
NDC in 2005 and had MCI in 2008 showed substantial
decrease in serum apoA1 (P 5 8.14E-04) and apoE
(P 5 .00102), although normal aging also showed
decreasing trends. Moreover, in group 3 (MCI-sMCI/
AD), serum levels of apoA1 (P 5 .00179) and apoE
(P 5 .00161) showed significant decrease during progres-
sion of the disease. TTR concentrations showed substan-
tial decrease in the NDC-MCI and MCI-sMCI/AD
groups but were not associated with normal aging
(Supplementary Table 2). Serum C4 levels increased in in-
dividuals with normal aging and those with progression of
the disease; MIP-4 levels did not significantly change
(Supplementary Fig. 1, left panel).
All data of the Tone cohort were also analyzed cross-
sectionally (Fig. 1 and Supplementary Fig. 1: right panels
and Supplementary Table 3). There was a significant
decrease of TTR (P5 .01264) and apoE (P5 .0278) among
the NDC, MCI, and sMCI/AD groups, and TTR levels
showed significant differences between NDC and sMCI/
AD (P 5 .02025; Fig. 1C and D). We also found that







Fig. 1. Serum levels of sequester proteins apoA1 (A), C3 (B), TTR (C), and apoE (D) during progression of cognitive impairment from 2005 to 2008 in the
longitudinal (left panel) and cross-sectional (right panel) studies from the Tone cohort. In the left panel, asterisks indicate significant changes in protein levels
between 2005 and 2008 samples. In the right panel, the bold solid bars within the boxplot represent the median abundance, and the solid bars represent mean
abundance for the given group. Open triangles are the highest and lowest values in each group. Error bars represent61.5 SD. Significant differences among the
three groups are indicated (Kruskal-Wallis test). In the longitudinal analysis, significant changes in protein levels between paired samples (Wilcoxon signed-
rank test) are indicated by (*). ApoA1: NDC-NDC (P 5 .00109), NDC-MCI (P 5 .00915), MCI-sMCI/AD (P 5 .03603), apoE: NDC-NDC (P 5 4.19E-04),
NDC-MCI (P5 .01285), andMCI-sMCI/AD (P5 .03603). In the cross-sectional analysis, significant changes in protein levels between two groups (Bonferroni
test) are likewise indicated (*). TTR: NDC versus sMCI/AD (P 5 .02025). Abbreviations: TTR, transthyretin; SD, standard deviation; NDC, nondemented
disease control; MCI, mild cognitive impairment; sMCI, stable mild cognitive impairment; AD, Alzheimer’s disease.
K. Uchida et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 270-280 273
K. Uchida et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 270-2802743.2. Cross-sectional analysis of serum apoA1, C3, and
TTR levels in the Tsukuba cohort
As shown in Table 1 and Fig. 2A–C(left panel; boxplots),
low levels of serum apoA1 (P5 4.44E-05), C3 (P5 .0126),
and TTR (P 5 4.07E-05) were found with progression of
cognitive impairment. ApoA1 and TTR seemed to gradually
decrease in individuals with aMCI and AD. On the other
hand, serum C3 was decreased in the aMCI group and was
the same or increased in the AD group. ApoE, C4, and
MIP-4 did not show statistically significant differences
among the groups (Supplementary Fig. 2).
As shown in Fig. 2A–C (right panel; ROC curve), three
sequester proteins distinguished MCI from NDC: apoA1
(AUC 5 0.64, sensitivity 78%, specificity 48%, P 5 .0124);
C3 (AUC 5 0.67, sensitivity 88%, specificity 48%,
P5.0033); andTTR(AUC5 0.62, sensitivity 80%, specificity
47%, P 5 .0298). The AD versus NDC comparison revealed
higher sensitivity and specificity in apoA1 (AUC5 0.76, sensi-
tivity 74%, specificity 71%,P,.0001) andTTR (AUC5 0.76,
sensitivity 74%, specificity 69%, P, .0001).
We categorized individuals according to MMSE score
into four groups (score 27–30 [n 5 71], 24–27 [n 5 34],
20–23 [n 5 17], and ,20 [n 5 20]) that were age-
matched and compared levels of these three sequester pro-
teins (Fig. 2D, Supplementary Table 4). Individuals with
lower MMSE scores had significantly decreased apoA1
(P 5 .00359) and TTR (P 5 .01894). Individuals with
MMSE scores ,20 showed significantly low levels of
apoA1 (P 5 .0396) and TTR (P 5 .05074) compared with
individuals with MMSE scores of 27–30.
C4, apoE, and MIP-4 did not show clinical potential to
distinguish aMCI or AD from NDC. C4 and apoE were
not significantly different among the groups categorized by
the MMSE score (Supplementary Figs. 2 and 3).
3.3. Multivariable statistical analysis of biomarker
proteins
All cross-sectional data from the Tsukuba cohort were
used for multivariable statistical analysis (Table 2A andTable 1
Characteristics of participants and serum levels of sequester proteins in MCI and
Characteristics NDC (n 5 49) aMCI (n
Age 69.8 6 12.4y 71.2 6
Male/female 33/16 21/3
MMSE score 28.8 6 1.6 26.7 6
ApoA1z 2345.3 6 918.0 1873.6 6
C3z 28.1 6 24.1 14.0 6
TTRz 520.5 6 144.8 445.0 6
Abbreviations: MCI, mild cognitive impairment; AD, Alzheimer’s disease; NDC
MMSE, mini-mental state examination; TTR, transthyretin; SD, standard deviatio
*Kruskal-Wallis test. Significant differences among the three groups are indica
yMean 6 SD.
zmg/mL.
xBonferroni test. Significant differences in NDC versus aMCI were observed in
jjBonferroni test. Significant differences in NDC versus AD were observed in aFig. 3A). In the LASSO regression, the optimal value of
parameter l was obtained by a combination of apoA1, C3,
and TTR. In the NDC versus aMCI comparison, AUC was
0.75 (P , .0001) with 90% sensitivity and 53% specificity.
In NDC versus AD, AUC was 0.79 (P , .0001) with 79%
sensitivity and 69% specificity. Addition of MMSE score
improved AUC values up to 0.83 and 1.00 in the MCI versus
NDC and AD versus NDC comparisons, respectively. These
results indicate that combination of C3, apoA1, and TTR
were clinically useful in the assessment of early stages of
cognitive impairment.3.4. Clinical performance of a set of sequester proteins as
biomarkers for cognitive decline in a prospective study
In the present study, we hypothesized that a combination
of biomarkers, specifically apoA1, C3, and TTR, would lead
to improved discrimination between cognitively normal in-
dividuals and those with MCI and AD. To confirm the clin-
ical potential of this multivariable statistical test, we
examined whether a combination of serum apoA1, C3, and
TTR could discriminate cognitive impairment at early stages
from NDC in a prospective study. We enrolled 258 partici-
pants and performed immunoassay of apoA1, C3 and
TTR, and MMSE (Supplementary Table 5).
We next calculated the probability of MCI in the 64
participants who had clinical diagnosis using equations
derived from the LASSO regression of the Tsukuba co-
horts. Characteristics of participants with clinical diag-
nosis and serum apoA1, C3, and TTR levels are
summarized in Table 3. Surprisingly, a combination of
C3, apoA1, and TTR was sufficient in discriminating
not only MCI but also pre-MCI from NDC with a high
ROC value (AUC 5 0.89, sensitivity 91% and specificity
80% in MCI versus NDC; AUC 5 0.82, sensitivity 77%
and specificity 80% in pre-MCI versus NDC; Table 2B,
Fig. 3B–D). Significant differences were observed in
NDC versus MCI (P 5 .00953) and NDC versus pre-
MCI (P 5 .01376). Addition of the MMSE score in the
equation resulted in more obvious discriminations.AD in the cross-sectional study of the Tsukuba cohort
5 51) AD (n 5 42) P value*
7.9 73.9 6 7.4 .27876
0 10/32
2.1 18.3 6 5.8 2.02E-18
594.4x 1665.3 6 431.8jj 4.44E-05
8.0x 21.5 6 15.9 .01264
144.8 357.0 6 122.1jj 4.07E-05
, nondemented disease control; aMCI, amnestic mild cognitive impairment;
n.
ted.
apoA1 (P 5 .00265) and C3 (P 5 3.74E-04).
poA1 (P 5 1.98E-05) and TTR (P 5 1.08E-02).
Fig. 2. Cross-sectional analysis of serum apoA1 (A), C3 (B), and TTR (C) levels and their corresponding levels according to the MMSE scores (D) in
the Tsukuba cohort. C-statistics analysis of the sequester proteins in MCI and AD is shown in the right panel. In boxplot, the bold solid bars within the
boxplot represent the median abundance, and the solid bars represent mean abundance for the given group. Open triangles are the highest and lowest
values in each group. Error bars represent 61.5 SD. Significant differences among three groups are indicated (Kruskal-Wallis test). Significant differ-
ence in protein levels between two groups are also indicated (Bonferroni test). Abbreviations: TTR, transthyretin; MMSE, mini-mental state examina-
tion; MCI, mild cognitive impairment; SD, standard deviation; aMCI, amnestic mild cognitive impairment; NDC, nondemented disease control; AD,
Alzheimer’s disease.
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The diagnosis of MCI and AD in the early stages is still a
challenge for general physicians at clinics and hospitals
because of the difficulty in determining the onset of nascent
and measurable cognitive impairment and also because of
the absence of reliable biomarkers. To our knowledge, this
is the first study to show the clinical utility of the Absequester protein as a biomarker in screening individuals
with cognitive decline, MCI, and AD.
In the cross-sectional and longitudinal cohort studies, we
found a set of sequester proteins, apoA1, C3, and TTR, that
were useful for the assessment of cognitive decline
(Supplementary Table 6). Multivariable statistical analysis
revealed that this set of serum proteins could discriminate
not only MCI and AD but also the early stages of cognitive
decline from NDC. Serum apoA1 and TTR showed
decreased levels in individuals with lower MMSE scores.
Because the MMSE score is included in the criteria for the
diagnosis of AD, AUC in AD versus NDC was expected to
improve. MCI and NDC are in the same range of the
MMSE score (24–30) by diagnostic criteria. Interestingly,
the MMSE score also improved AUC in NDC versus MCI.
Serum levels of TTR and apoA1 were found to grad-
ually decrease during the progression of cognitive
decline in individuals with sMCI and AD. On the other
hand, C3 levels were observed to decrease during the
early stages of cognitive decline. ApoA1 and TTR
showed similar decreasing trends during the progression
of cognitive decline. A hypothetical model of dynamic
AD biomarkers related to the pathologic cascade was
proposed by Jack et al. [21]. A series of pathologic
events leading to cognitive impairment occur before at-
rophy of certain brain areas can be detected by magnetic
resonance imaging. Notably, these events occur more
than 10–20 years before the onset of AD. The term “pre-
clinical stage” is now generally accepted as the initial
process of AD pathogenesis. The serum levels of
apoA1, C3, and TTR may decrease during progression
from a cognitively normal state to preclinical AD and
MCI. Differences in protein levels between NDC and
MCI/AD in the Tone cohort seemed to be obscured
compared with those in the Tsukuba and Uji cohorts.
This may be explained by the fact that sequester proteins
tend to decrease with normal aging; thus, the higher
average age (by 6–9 years) of the participants in the
Tone cohort, compared with those of other two cohorts,
may have affected the results.
Diabetes mellitus has been reported to increase the risk
for dementia including AD [22,23]. However, in this study,
we did not have sufficient data on fasting serum samples.
Further studies would be needed to analyze whether
environmental and biological factors affect the levels of
these sequester proteins.
ApoA1 is the main protein constituent of high-density li-
poproteins and is well-known for its important role in
reverse cholesterol transport. Ab binds to cholesterols,
such as apoA1 and apoE, at the blood-brain barrier [24].
Moreover, there are decreased levels of apoA1 in CSF of
patients with AD [25,26]. There was a significant
association between the APOE ε4 allele and AD [27]. In
this study, there was no significant change in serum levels
of apoE during progression of the disease. It should be
noted that literature varies on apoE protein levels in CSF
Table 2
Clinical potential of a set of three sequester proteins as biomarker for pre-MCI, MCI, and AD analyzed by LASSO regression
Disease Biomarker Sensitivity (%) Specificity (%) AUC 95% CI P value Criterion
(A) Discrimination of MCI or AD from NDC in the cross-sectional study of the Tsukuba cohort
aMCI versus NDC ApoA1 90 53 0.75 0.654–0.832 ,.0001 0.43
C3
TTR
AD versus NDC ApoA1 79 69 0.79 0.687–0.865 ,.0001 0.46
C3
TTR








(B) Discrimination of pre-MCI or MCI from NDC in the prospective study of the Uji cohort
pre-MCI versus NDC ApoA1 77 80 0.82 0.655–0.927 ,.0001 0.65
C3
TTR
MCI versus NDC ApoA1 91 80 0.89 0.731–0.971 ,.0001 0.65
C3
TTR








Abbreviations: MCI, mild cognitive impairment; AD, Alzheimer’s disease; LASSO, least absolute shrinkage and selection operator; AUC, area under the
curve; CI, confidence interval; NDC, nondemented disease control; TTR, transthyretin; aMCI, amnestic mild cognitive impairment.
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in this study because reproducible results were not obtained
in a pilot experiment. ApoJ may cooperatively regulate Ab
clearance and aggregation with apoE [30]; however, levels
of these peripheral proteins in AD vary in literature [31,32].
The complement system consists of a series of proteins
that are important co-factors in chronic neurodegenerative
disorders such as AD [33]. Innate immunity is recognized
to play a major role in an individual’s susceptibility to neuro-
degenerative disorders. Both classic and alternative path-
ways are associated with Ab pathogenesis [34]. Decreased
levels of inactivated form of C3 were observed in MCI in
our cross-sectional studies. Individuals with lower levels
of inactive C3 may have susceptibility to cognitive decline
because of low Ab sequestration function, although low
C3 levels were also observed in normal aging.
TTR is a 55 kDa homotetrameric protein mainly pro-
duced in the liver and choroid plexus of the brain, and
it is secreted in the periphery and CSF [35]. Most previous
reports have presented results of decreased CSF levels of
TTR in AD [36,37]. Plasma TTR levels are lower in
participants with cognitive decline and AD compared
with those in cognitive normal controls [38,39].Thus, it is possible that decreasing peripheral availability
of C3, apoA1, and TTR results in the failure of these proteins
to protect against disease progression via Ab sequestration.
Monitoring of the progression of neuropathologic changes
in asymptomatic stages of AD by biomarkers is important
for early intervention, which may help prevent AD progres-
sion or may result to more effective treatment. The proteins
analyzed in this study to be involved in the sequestration of
Ab are not directly related to neuropathologic changes of the
synapse; rather, they are involved in protection of the syn-
apse against Ab toxicity during progression of cognitive
impairment. Thus, lower levels of sequester proteins may
lead to synaptic damage in the preclinical stages of AD path-
ogenesis.
Sequester proteins other than apoA1, C3, and TTR did
not show clinical potential for the assessment of cognitive
decline. Serum protein levels of some sequester proteins
may vary by circumstances or genetic factors and did
not show significant changes. In several studies, serum al-
bumin was shown to bind to Ab oligomers [40,41]. We
measured the serum albumin concentration among
disease groups in the Tone cohort; however, there was
no significant difference in the albumin levels, both
AB
C D
Fig. 3. Evaluation of clinical potential of a set of serum apoA1, C3, and TTR in the cross-sectional (A and B; C-statistics) and prospective studies using
LASSO regression model (C and D; boxplots). Significant differences were observed in NDC versus pre-MCI and NDC versus MCI (C). Addition of the
MMSE score to these protein levels in LASSO analysis increased clinical potential (D; NDC versus pre-MCI [P 5 2.49E-04], NDC versus MCI
[P 5 2.93E-08], NDC versus AD [P 5 1.09E-11], pre-MCI versus MCI [P 5 .01016], MCI versus AD [P 5 1.48E-04], and pre-MCI versus AD
[P 5 8.82E-08]). The bold solid bars within the boxplot (C, D) represent the median abundance, and the solid bars represent mean abundance for the given
group. Open triangles are the highest and lowest values in each group. Error bars represent 61.5 SD. Kruskal-Wallis test was used to determine statistical
significance among the groups, and Bonferroni test was used in the two-group comparison. Schematic model of changes of serum sequester protein levels
with progression of cognitive impairment. (E). Serum levels of C3 and apoA1 show decreased trends in early stages in cognitive impairment and apoA1
continues to decrease in progression to AD. Serum TTR levels was not changed in cognitive decline at early stage but decreased in MCI and AD. Abbre-
viations: TTR, transthyretin; LASSO, least absolute shrinkage and selection operator; NDC, nondemented disease control; MCI, mild cognitive impairment;
AD, Alzheimer’s disease; aMCI, amnestic mild cognitive impairment; AUC, area under the curve.
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(P 5 .93611; data not shown).
Larger scale population studies are still required to
show the clinical utility of these sequester proteins for
risk assessment of the progression of cognitive decline at
the preclinical stage. We confirmed these results using a
conventional in vitro diagnostics assay that is available
in most clinical chemistry laboratories (unpublished
data). This and other similar studies are crucial for the
development of blood-based screening methods to detectnot only early MCI but also preclinical AD. Early detec-
tion of cognitive impairment may ultimately reduce the
incidence of dementia.Acknowledgments
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1. Systematic review: The authors reviewed literature on
PubMed sources and Web sites that described blood-
based biomarkers for cognitive decline. Numerous
reports described cerebral fluid biomarkers for Alz-
heimer’s disease (AD). Although amyloid b in the
blood has been expected to be an AD biomarker, it is
not clinically useful in terms of reproducibility.
2. Interpretation: We showed the usefulness of
sequester proteins involved in amyloid b clearance
to evaluate cognitive decline and progression of
cognitive impairment in three cohort studies. The
current results are consistent with the hypothesis
that individuals with decreased levels or impaired
function of the sequester proteins are susceptible to
cognitive impairment.
3. Future directions: The article proposes a simple
blood test for risk assessment of cognitive decline.
Further investigation is required on (1) the clinical
usefulness of a set of biomarkers by larger scale pop-
ulation study and (2) the relationship between low
levels of sequester proteins and synapse damage dur-
ing progression of cognitive impairment.References
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